606144-04-1

Basic information

• Product Name: 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benzo[d]iMidazole-6-carboxylic acid
• Synonyms: 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benzo[d]iMidazole-6-carboxylic acid;6-(4-broMo-2-chlorophenylaMino)-7-fluoro-3-Methyl-3H-benzo[d]iMidazole-5-carboxylic acid;6-(4-Bromo-2-chlorophenylamino)-7-fluoro-3-methyl-benzimidazole-5-carboxylic acid;1H-BenziMidazole-6-carboxylic acid,5-[(4-broMo-2-chlorophenyl)aMino]-4-fluoro-1-Methyl-;6-(4-bromo-2-chloroanilino)-7-fluoro-3-methylbenzimidazole-5-carboxylic acid
• CAS NO: 606144-04-1
• Molecular Formula: C₁₅H₁₀BrClFN₃O₂
• Molecular Weight: 398.6142032
• Mol File: 606144-04-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 507.6±60.0 °C(Predicted)
• Appearance: /
• Density: 1.75±0.1 g/cm3(Predicted)
• PKA: 4.18±0.10(Predicted)
• CAS DataBase Reference: 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benzo[d]iMidazole-6-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benzo[d]iMidazole-6-carboxylic acid(606144-04-1)
• EPA Substance Registry System: 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benzo[d]iMidazole-6-carboxylic acid(606144-04-1)

Safety Data

• Hazardous Substances Data: 606144-04-1(Hazardous Substances Data)

Usage

General Description

5-(4-bromo-2-chlorophenylamino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid is a chemical compound with potential biological activity, potentially useful in pharmaceutical research or as a reference standard. It is a benzoimidazole derivative with a carboxylic acid group, a methyl substituent, and a fluorine atom. The compound also contains a bromine and a chlorine atom, adding to its complexity and potential reactivity. The presence of the amino group and the carboxylic acid group suggests that the compound may have some degree of solubility in aqueous solutions, making it potentially useful for biological assays or in medicinal chemistry applications. Its exact properties and potential uses in pharmaceuticals or research would need to be further investigated.

Upstream product

• 917980-15-5 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carbonitrile 
• 606144-02-9 methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylate 
• 918321-20-7 methyl 5-amino-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate 
• 31928-47-9 4-bromo-2-chloroiodobenzene 
• 1000340-06-6 methyl 5-[(4-bromophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylate 
• 606093-58-7 4-Amino-3-fluoro-5-nitro-2-phenylamino-benzoic acid methyl ester 
• 606143-46-8 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 197520-71-1 2,3,4-trifluoro-5-nitro-benzoic acid 
• 284030-57-5 4-amino-2,3-difluoro-5-nitro-benzoic acid 
• 284030-58-6 4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 
• 606093-59-8 7-Fluoro-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 

Downstream Products

• 606144-05-2 5-[(4-bromo-2-chlorophenyl)amino]-N-[2-(ethenyloxy)ethoxy]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxamide 
• 606143-52-6 selumetinib 

Relevant articles and documents

Synthesis method of semetinib

The invention relates to a synthesis method of simetinib. According to the method, diethoxymethane is creatively adopted as a ring closing reactant, and two-step reaction of ring closing reaction and methylation is combined into one step, so the yield is

Substituted benzimidazole compound and composition with compound

The invention provides a substituted benzimidazole compound and a composition with the compound. The substituted benzimidazole compound is a compound of formula (I) as shown in the specification, or apharmaceutically acceptable salt, prodrug, aquo-complex or solvent compound, polycrystalline type compound, stereisomer or isotope variant of the compound. The compound provided by the invention canbe adopted to treat and/or prevent related diseases caused by MEK (Methyl Ethyl Ketone), such as excessive proliferative diseases, pancreatitis, kidney illness, blastocyte cell transplantation and angiogenesis or angiopoiesis related diseases.

PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS

Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-1 and their synthetic intermediates: wherein Z, X1, X2, X5, R2 and R10 are as defined herein. Compounds of Formula Ia-1 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.